Iron repletion is associated with reduction in platelet counts in non-dialysis chronic kidney disease patients independent of erythropoiesis- stimulating agent use: A retrospective cohort study

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Yessayan, Lenar ^a   Yee, Jerry ^a   Zasuwa, Gary ^a   Frinak, Stan ^a   Besarab, Anatole ^b  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Erythropoietin; Intravenous iron dextran; Iron deficiency anemia; Platelet count; Thrombocytosis

Indexed keywords

ANTIANEMIC AGENT; IRON;

AGED; ANEMIA, IRON-DEFICIENCY; BLOOD; COHORT ANALYSIS; DRUG EFFECTS; ERYTHROPOIESIS; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; COHORT STUDIES; ERYTHROPOIESIS; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; MALE; MIDDLE AGED; PLATELET COUNT; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES;

EID: 84905158323     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-119     Document Type: Article

References (33)

1. Thrombopoietin: the primary regulator of platelet production. Kaushansky K, Blood 1995 86 2 419 431
2. Megakaryocyte-related interleukins in reactive thrombocytosis versus autonomous thrombocythemia. Haznedaroglu IC, Ertenli I, Ozcebe OI, Kiraz S, Ozdemir O, Sayinalp NM, Dundar SV, Calguneri M, Kirazli S, Acta Haematol 1996 95 2 107 111 (Pubitemid 26110053)
3. Positive and negative regulation of megakaryocytopoiesis. Wendling F, Han ZC, Baillieres Clin Haematol 1997 10 1 29 45 (Pubitemid 27192454)
4. Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis. Hsu HC, Tsai WH, Jiang ML, Ho CH, Hsu ML, Ho CK, Wang SY, J Lab Clin Med 1999 134 4 392 397
5. Interaction of monocytes and T cells in the regulation of normal human megakaryocytopoiesis in vitro: role of IL-1 and IL-2. Hamaguchi H, Takano N, Saito K, Enokihara H, Furusawa S, Shishido H, Br J Haematol 1990 76 1 12 20 (Pubitemid 20326789)
6. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Alexandrakis MG, Passam FH, Moschandrea IA, Christophoridou AV, Pappa CA, Coulocheri SA, Kyriakou DS, Am J Clin Oncol 2003 26 2 135 140 (Pubitemid 36443554)
7. Effects of interleukin-1 and tumor necrosis factor on megakaryocytopoiesis: mechanism of reactive thrombocytosis. Dan K, Gomi S, Inokuchi K, Ogata K, Yamada T, Ohki I, Hasegawa S, Nomura T, Acta Haematol 1995 93 2-4 67 72
8. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Broudy VC, Lin NL, Kaushansky K, Blood 1995 85 7 1719 1726
9. Synergistic and inhibitory interactions in the in vitro control of murine megakaryocyte colony formation. Metcalf D, Di Rago L, Mifsud S, Stem Cells 2002 20 6 552 560 (Pubitemid 35463068)
10. Human platelets display high-affinity receptors for thrombopoietin. Broudy VC, Lin NL, Sabath DF, Papayannopoulou T, Kaushansky K, Blood 1997 89 6 1896 1904 (Pubitemid 27132103)
11. Effect of recombinant human erythropoietin on platelets in patients with anemia of renal failure: correlation of platelet count with erythropoietic activity and iron parameters. Beguin Y, Loo M, R'Zik S, Sautois B, Lejeune F, Rorive G, Fillet G, Eur J Haematol 1994 53 5 265 270
12. Erythropoietin and platelet production. Beguin Y, Haematologica 1999 84 6 541 547 (Pubitemid 29323264)
13. De novo once-monthly darbepoetin alpha treatment for the anemia of chronic kidney disease using a computerized algorithmic approach. Chalhoub E, Frinak S, Zasuwa G, Faber MD, Peterson E, Besarab A, Yee J, Clin Nephrol 2011 76 1 1 8
14. Intravenous iron dextran as a component of anemia management in chronic kidney disease: a report of safety and efficacy. Yessayan L, Sandhu A, Besarab A, Yessayan A, Frinak S, Zasuwa G, Yee J, Int J Nephrol 2013 2013 703038
15. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Khorana AA, Francis CW, Culakova E, Lyman GH, Cancer 2005 104 12 2822 2829 (Pubitemid 41798294)
16. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Simanek R, Vormittag R, Ay C, Alguel G, Dunkler D, Schwarzinger I, Steger G, Jaeger U, Zielinski C, Pabinger I, J Thromb Haemost 2010 8 1 114 120
17. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. Zakai NA, Wright J, Cushman M, J Thromb Haemost 2004 2 12 2156 2161 (Pubitemid 40185776)
18. Iron deficiency anemia with marked thrombocytosis complicated by central retinal vein occlusion. Nagai T, Komatsu N, Sakata Y, Miura Y, Ozawa K, Intern Med 2005 44 10 1090 1092 (Pubitemid 41715761)
19. Cerebral venous sinus thrombosis associated with iron deficiency: two case reports. Kinoshita Y, Taniura S, Shishido H, Nojima T, Kamitani H, Watanebe T, Neurol Med Chir (Tokyo) 2006 46 12 589 593 (Pubitemid 46021212)
20. Anemia as a risk factor for cerebral venous thrombosis? An old hypothesis revisited. Results of a prospective study. Stolz E, Valdueza JM, Grebe M, Schlachetzki F, Schmitt E, Madlener K, Rahimi A, Kempkes-Matthes B, Blaes F, Gerriets T, Kaps M, J Neurol 2007 254 6 729 734 (Pubitemid 47012446)
21. Correction of anemia with epoetin alfa in chronic kidney disease. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, N Engl J Med 2006 355 20 2085 2098 (Pubitemid 44749317)
22. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA, N Engl J Med 1998 339 9 584 590 (Pubitemid 28385655)
23. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, N Engl J Med 2009 361 21 2019 2032
24. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Streja E, Kovesdy CP, Greenland S, Kopple JD, McAllister CJ, Nissenson AR, Kalantar-Zadeh K, Am J Kidney Dis 2008 52 4 727 736
25. Thrombopoietic cytokines in patients with iron deficiency anemia with or without thrombocytosis. Akan H, Guven N, Aydogdu I, Arat M, Beksac M, Dalva K, Acta Haematol 2000 103 3 152 156
26. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. Aggarwal HK, Nand N, Singh S, Singh M, Hemant, Kaushik G, J Assoc Phys o India 2003 51 170 174 (Pubitemid 44227894)
27. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Charytan C, Qunibi W, Bailie GR, Nephron Clin Pract 2005 100 3 55 62
28. Ferumoxytol for treating iron deficiency anemia in CKD. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ, J Am Soc Nephrol 2008 19 8 1599 1605
29. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Stoves J, Inglis H, Newstead CG, Nephrol Dial Transplant 2001 16 5 967 974 (Pubitemid 32440369)
30. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S, Kidney Int 2005 68 6 2846 2856 (Pubitemid 43251032)
31. Intravenous iron repletion does Not significantly decrease platelet counts in CKD patients with iron deficiency anemia. Dossabhoy NR, Gascoyne R, Turley S, Int J Nephrol 2013 2013 878041
32. Erythrocyte and reticulocyte indices in the assessment of erythropoiesis activity and iron availability. Urrechaga E, Borque L, Escanero JF, Int J Lab Hematol 2013 35 2 144 149
33. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, Korbet S, Krantz SB, Lundin AP, Nissenson AR, Ogden DA, Paganini EP, Rader B, Rutsky EA, Stivelman J, Stone WJ, Teschan P, Van Stone JC, Van Wyck DB, Zuckerman K, Adamson JW, Ann Intern Med 1989 111 12 992 1000 (Pubitemid 20034923)